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Photoimmunoprotection by UVA (320–400 nm)
Radiation Is Determined by UVA Dose and Is
Associated with Cutaneous Cyclic Guanosine
Monophosphate
Munif Allanson1, Diane Domanski1 and Vivienne E. Reeve1
The immunomodulating properties of UVA radiation remain controversial. Here, we demonstrate in female
inbred Skh:hr-1 mice that single subinflammatory UVA exposures between 1.61 and 580.5 kJ/m2 are not
immunosuppressive. Furthermore, UVA exposures between 16.13 and 580.5 kJ/m2 provided dose-related
immunoprotection against UVB-induced immunosuppression. Higher UVA exposures (870.8–1,161 kJ/m2)
became inflammatory and immunosuppressive alone, and lost the photoimmunoprotective capacity. We
previously reported that UVA photoimmunoprotection depends on the induction of cutaneous heme
oxygenase-1, particularly its enzymatic product, carbon monoxide (CO). CO was suggested to activate
cutaneous guanylyl cyclase (GC), as the specific GC inhibitor, 1H-(1,2,4)oxadiazolo-(4,3-a)quinoxalin-1-one
(ODQ), abrogated CO photoimmunoprotection in the mouse. This study shows that cutaneous cyclic
guanosine monophosphate (cGMP) concentration increased only following immunoprotective UVA doses, or
immunoprotective topical CO treatment, and cGMP production was inhibited by ODQ. Conversely, cGMP
concentration was increased by inhibition of its degradative phosphodiesterase (PDE) with topical sildenafil.
The PDE-5 isoform was identified in normal mouse skin. Subsequently, a moderate concentration of sildenafil
was shown to simulate the effect of UVA in protecting against photoimmunosuppression by solar-simulated UV
radiation or its mediator cis-urocanic acid. Thus, cutaneous cGMP, controlled by its synthesis via CO-activated
GC and its degradation by PDE-5, is strongly associated with UVA photoimmunoprotection.
Journal of Investigative Dermatology (2006) 126, 191–197. doi:10.1038/sj.jid.5700050
INTRODUCTION
In spite of the evidence indicating that the UVA waveband
can be immunosuppressive in mice (Bestak and Halliday,
1996; Iwai et al., 1999; Ngheim et al., 2001) and in humans
(Damian et al., 1999; Dumay et al., 2001) and can even be
carcinogenic in fish and rodents (Setlow et al., 1993; de Laat
et al., 1997), an alternate and growing body of data now
demonstrates that moderate doses of UVA radiation may not
induce immunosuppression or carcinogenesis in mice (Reeve
et al., 1998; De Fabo et al., 2004), in guinea-pigs (Menzies
et al., 2004), or in humans (Skov et al., 1997; Hofmann-
Wellenhof et al., 2004). A recent study investigating the UVA
dose dependence for immunomodulation in C57BL mice
reported that a medium dose of UVA equivalent to the UVA
content of 0.5minimal erythemal dose of solar UV
radiation, administered on 3 consecutive days, was immu-
nosuppressive, but lower and higher doses were inert (Byrne
et al., 2002). However, in Balb/c mice, these UVA exposures
had no immunological effect (Byrne et al., 2002). In contrast,
single exposures of mice to suberythemogenic UVA irradia-
tion in a higher dose range have been found to be
immunologically inert in C57BL and Skh:hr-1 hairless mice
(Reeve et al., 1998, 1999). Thus, the dose dependency of the
immunomodulatory effects of UVA radiation remains un-
clear, and it appears that there may be spectral, dose
fractionation, and genetic determinants for the response at
least in the mouse.
Interestingly, in a number of studies, the UVA waveband
has been shown to provide immunoprotection against the
suppressive effects of UVB (290–320 nm) irradiation, or of the
epidermal UVB photoproduct, cis-urocanic acid (cis-UCA)
(Reeve et al., 1998; Skov et al., 2000; Garssen et al., 2001;
Khaskhely et al., 2001; Allanson and Reeve, 2005). Mechan-
istic studies in mice have implicated the increased enzyme
activity of the stress protein heme oxygenase-1 (HO-1) in the
skin (Reeve and Tyrrell, 1999; Reeve and Domanski, 2002),
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supported by the increased expression of HO-1 mRNA and
protein in both epidermal and dermal cells of the mouse skin
(Allanson and Reeve, 2004). The enzymatic products of HO-1
are free Fe2þ , biliverdin, which is rapidly converted to
bilirubin by the ubiquitous biliverdin reductase, and gaseous
carbon monoxide (CO) (Maines, 1997), and recent data
indicate that it is CO that provides the photoimmunoprotective
properties of UVA. Topically applied CO-releasing molecule
(CO-RM) can mimic the immunomodulating action of UVA
radiation in mice (Allanson and Reeve, 2005). This is consistent
with the evidence that CO is a potent signalling molecule that
has anti-inflammatory (Otterbein et al., 2000), antiapoptotic
(Brouard et al., 2000), antiproliferative (Peyton et al., 2002;
Song et al., 2002; Durante, 2003), and immunomodulating
(Van Uffelen et al., 1996; Ndisang et al., 1999) properties,
similar to nitric oxide (NO). Furthermore, preliminary evidence
suggests that UVA-induced CO in the mouse skin acts via
soluble guanylyl cyclase (GC), a heme protein and proven
receptor for NO (Hofmann et al., 2000; Otterbein et al., 2003),
since treatment with a selective inhibitor of GC, 1H-
(1,2,4)oxadiazolo-(4,3-a)quinoxalin-1-one (ODQ), abrogated
the UVA protection against both solar-simulated UV radiation
(SSUVR) and cis-UCA (Allanson and Reeve, 2005).
In various cell types, the binding of CO to GC is known to
generate cyclic guanosine monophosphate (cGMP), an
intracellular signalling molecule that is involved in protein
phosphorylation and calcium ion channels (Kharitonov et al.,
1995). The cGMP level in cells is determined not only by the
GC activity but also by the enzymes that degrade it, the
phosphodiesterases (PDEs). The family of PDEs comprises
numerous isoforms, of which PDE5 appears to be most
universally active in many tissues. However, very little is
known about this pathway in the skin. Here, we have
investigated the state of the immune function, measured as
contact hypersensitivity (CHS) in the Skh:hr-1 hairless mouse,
in relation to a wide range of UVA exposure doses alone and
combined with immunosuppressive UVB, SSUVR, or cis-
UCA treatment. Furthermore, the relationship between
cutaneous cGMP level, GC activity, and PDE activity has
been studied in the mouse skin in response to these UVA
doses, or to topically applied CO-RM, utilizing specific
inhibition of GC and PDE5, and correlating these activities
with the CHS response.
RESULTS
UVA dose dependence for suppression of CHS and induction of
inflammation
Measurement of the effect on CHS of single UVA exposures
to doses from 1.61 to 580.5 kJ/m2 revealed no statistically
significant differences from unexposed skin (Figure 1). How-
ever, at 870.8 kJ/m2 of UVA, there was significant suppression
of CHS by 14% (Po0.05), and the suppression increased to
20% (Po0.001) after 1,161 kJ/m2. Thus, a window of UVA
exposure doses that are not immunosuppressive exists, but
when exceeded, UVA irradiation will increasingly induce
suppression of CHS. At none of the tested UVA doses was
there a significant increase in skinfold, denoting edematous
inflammation, observed at 24 hours postirradiation.
UVA dose dependence for immunoprotection against UVB
The capacity for photoimmunoprotection against UVB was
UVA dose dependent, and was increasingly evident and
statistically significant between 16.13 and 580.5 kJ/m2 UVA,
with optimal immunoprotection by UVA doses of 387 and
580.5 kJ/m2 (Figure 2). No photoimmunoprotection against
UVB was detected at UVA doses less than 16.13 kJ/m2, but
UVA doses of 870.8 kJ/m2 and greater, which were shown to
be immunosuppressive alone, finally added to the UVB
suppression and significantly augmented the degree of
suppression at 1,161 kJ/m2.
The effect that the immunomodulating UVA exposures
between 387 and 1,161 kJ/m2 might have on the UVB-
induced inflammatory reaction of the skin was measured as
skinfold thickness at 24 hours postirradiation (Figure 3). These
UVA exposures alone did not increase skinfold thickness.
However, when UVA was combined with the inflammatory,
3minimal edematous dose (MEdD) UVB irradiation, there
was a UVA dose-related modulation of the inflammation in
response to UVB, such that 387 and 580.5 kJ/m2 UVA
1,161
870.8
580.5
387
193.5
96.8
48.4
16.13
8.06
4.03
1.61
0
0 10 20 30 40 50
Average ear swelling (mm × 0.01± SEM)
UV
A 
do
se
 (k
J/m
2 )
*P<0.05
**P<0.001
**
*
* **
Figure 1. The CHS reaction to oxazolone in groups of five mice, following a
single exposure to increasing doses of UVA radiation, measured as average
ear swelling. Only the highest UVA doses tested caused significant systemic
suppression of CHS.
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Figure 2. Effect of single exposures to increasing doses of UVA radiation on
the immunosuppression caused by a subsequent exposure to 3MEdD of
UVB radiation, measured by the CHS reaction to oxazolone in groups of five
mice.
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progressively reduced UVB inflammation to a significant
level (Po0.05). When UVA exposure was increased to 870.8
and 1,161 kJ/m2, the protective anti-inflammatory effect was
progressively lost.
UVA dose dependence for the induction of cutaneous cGMP
UVA induction of cutaneous cGMP was measured after UVA
exposures that had been found to have immunomodulating
properties. A significant increase (Po0.01) in cGMP of 24%
was observed after 193.5 kJ/m2 UVA; cGMP was more
strongly increased by 80% (Po0.01) after 387 kJ/m2 UVA
(Figure 4), but was not significantly elevated in response to
580.5 kJ/m2 or higher UVA exposures. Thus, a significant
increase in cGMP correlated with those UVA exposures
(193.5 and 387 kJ/m2) that also induced optimal photoimmu-
noprotection, but was not evident with higher UVA doses that
became immunosuppressive and were no longer protective
against UVB suppression. The concentration of cGMP was
also not increased after the lowest tested UVA dose of 96.8
kJ/m2, a dose that had been found to be significantly immuno-
protective (Figure 2). This suggests that while cGMP con-
centration appears to be a major determinant of UVA
photoimmunoprotection, other pathways may also be active.
Time course of UVA-induced cutaneous cGMP production
The cutaneous cGMP concentration was already measurably
increased at the completion of UVA exposure to 387 kJ/m2,
and continued to increase by approximately 50% until
48 hours post-UVA, following which there was a reduction
to the unirradiated skin level by 72 hours (Figure 5). This
suggested an activation of PDE enzyme activity to degrade
the elevated cGMP and restore the tissue level to normal.
Regulation of cutaneous cGMP by GC and PDE
Both CO-RM and UVA (387 kJ/m2) caused significant
increases in cGMP (Figure 6). The GC inhibitor ODQ
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Figure 3. Effect of single exposures to increasing doses of UVA radiation on
the edematous inflammation induced by a subsequent exposure to 3MedD
of UVB radiation, measured in groups of five mice as the mid-dorsal skinfold
thickness at 24 hours. UVA doses between 387 and 1,161 kJ/m2 alone did not
induce edema.
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Figure 4. Average cutaneous cGMP concentration, measured by ELISA, at
48 hours following single exposures to increasing doses of UVA radiation,
compared with unirradiated skin (n¼ 3).
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Figure 5. Time course of average cutaneous cGMP concentration, measured
by ELISA, following irradiation with 387 kJ/m2 UVA (n¼3).
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Figure 6. Regulation of the average cutaneous cGMP concentration by UVA
radiation (387 kJ/m2) or 500 lM CO-RM treatment, alone or combined with
subsequent topical treatments with ODQ, and the effect of topical sildenafil
(0.01 mg/ml) treatment (n¼ 3).
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markedly reduced cutaneous cGMP concentration, and
abrogated the UVA- and CO-RM-induced increase. In
contrast, the specific PDE5 inhibitor sildenafil significantly
increased the cGMP concentration, supporting the concept of
the balance of GC and PDE in regulating cGMP in the skin.
PDE5 gene activity was detected constitutively by reverse
transcriptase (RT)-PCR in mouse skin (Figure 7). Evidence for
possible inhibition by UVA radiation of PDE5 enzyme
activity, measured by the consumption of cGMP or cAMP
in in vitro incubations of skin homogenates, was sought.
However, there was no effect of 387 kJ/m2 UVA irradiation
on this enzyme in vivo (Table 1), implicating activated GC as
the major indirect UVA target, responding to the UVA-
released CO in the skin to elevate the cGMP concentration.
Regulation of photoimmune responses by PDE activity
Topical sildenafil treatment between 0.001 and 0.1 mg/ml
did not significantly affect the CHS reaction in mice (Figure 8).
In mice irradiated with an immunosuppressive dose of
SSUVR, neither 0.001 nor 0.1 mg/ml sildenafil had an effect.
However, the intermediate concentration of the inhibitor,
0.01 mg/ml sildenafil, strongly prevented the SSUVR-induced
suppression of CHS. In addition, 0.01 mg/ml sildenafil also
prevented the suppression of CHS by the UVB photoproduct,
cis-UCA (Figure 8). This suggested a window of physiologi-
cally functional sildenafil concentrations that may have
immunoprotective activity.
DISCUSSION
This study presents a systematic assessment of the dose
dependence for UVA radiation to suppress the CHS response
in the hairless mouse. We report that the very low doses of
UVA, such as those within the range previously used by
others in C57BL/6 and Balb/C mice (Byrne et al., 2002), in
which a biphasic dose-related immunological response was
described, showed no evidence of immunosuppression, and
only the highest UVA doses tested, which are equivalent to
the UVA content of approximately 37–50MEdD of SSUVR
in this mouse, became both inflammatory and immunosup-
pressive dose-responsively. The capacity of this range of UVA
exposure doses to interact protectively with the immunosup-
pressive properties of UVB radiation was found to depend
closely on the UVA dose. A window of increasingly
immunoprotective UVA doses was established, approximat-
ing the UVA content of between 0.7 and 25MEdD of
SSUVR, that optimally reduced UVB suppression of CHS by
approximately 72%. It is not clear why our results differ from
those of Byrne et al. (2002). However, there are differences in
mouse strains, which may be relevant since the C57BL and
Balb/c strains reacted differently (Byrne et al., 2002), and
differences in the spectral properties of the UV sources so that
our fluorescent tube UVA spectrum was slightly deficient in
the waveband between 380 and 400 nm by comparison with
the Xe arc source (Reeve and Domanski, 2002). Furthermore,
we have irradiated the mice in a single exposure, whereas
Byrne et al. repeated their irradiation on three successive
days. This may have important immunological conse-
quences, as it has been demonstrated that a repeated UVA
exposure at 24 hours of both cultured human skin fibroblasts
(Noel and Tyrrell, 1997) and of hairless mice resulted in a
transient refractoriness of the HO-1 gene and HO enzyme
activity, and in the mouse, this correlated with a transient
refractoriness of the immunoprotective properties of the UVA
against both UVB and cis-UCA (Reeve and Domanski, 2002).
Whether the refractoriness is dependent on UVA dose has yet
to be demonstrated.
Since it has been previously established that HO-derived
CO can account for the photoimmunoprotection of UVA
radiation and that CO may act via the GC pathway (Allanson
and Reeve, 2005), it was consistent to find that the cGMP
levels measured in the mouse skin were elevated by the UVA
a b c a b c
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Figure 7. Identification of PDE5 mRNA in the skin of three hairless mice
(a–c) by RT-PCR, compared with constitutive presence of HO-2 mRNA.
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Figure 8. The CHS reaction to oxazolone in groups of five mice, measured as
average ear swelling, following immunosuppressive treatments with SSUVR
or cis-UCA, and topical application of sildenafil lotions.
Table 1. Effect of UVA irradiation (387 kJ/m2) on
cutaneous PDE enzyme activity, measured as the
degradation of cGMP and cAMP exogenous substrates,
in extracts of normal and UVA-irradiated hairless
mouse skin (n=3)
Treatment
cGMP degraded
(pmol/mg skin
protein/h)
cAMP degraded
(pmol/mg skin
protein/h)
NIL 10.1970.36 (SEM) 1.8570.35
UVA irradiated 9.9670.40 1.9770.20
SEM=standard error of mean.
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doses that were immunoprotective, but not by higher UVA
exposures. The cutaneous cGMP concentration was seen to
increase progressively up to 48 hours post-UVA exposure,
after which it decreased to the normal level within the next
24 hours. This suggested that elevated cGMP might activate
its own degradation by upregulating the ubiquitous PDEs that
have been described in many organs. Such regulatory control
by cGMP binding to and activating PDE5 specifically has
been described in vitro (Okada and Asakawa, 2002) and in
the rat lung (Cohen et al., 1996). However, although PDE
inhibitors have been used in dermatology to treat various
inflammatory skin diseases (Bruynzeel et al., 1998), the
definitive presence of the PDE5 isoform in skin has not been
identified. Here, we demonstrate PDE5 presence in hairless
mouse skin, and by treating mice topically with its specific
inhibitor sildenafil, we have revealed a therapeutic concen-
tration of this drug that, like UVA irradiation, effectively
abrogated suppression of CHS by SSUVR or by cis-UCA, and
significantly elevated the concentration of cGMP in the
mouse skin. In contrast, the topical treatment of the mice with
the GC inhibitor ODQ, previously shown to prevent CO-
induced photoimmunoprotection (Allanson and Reeve,
2005), was found to abrogate the UVA or CO induction of
cGMP. Thus, the balance of GC and PDE5 activities in the
skin can be seen to determine the level of cGMP, and
therefore to have strong immunoregulatory potential.
The possibility that UVA irradiation might result in
elevated cGMP levels by directly inhibiting cutaneous PDE
enzyme activity was examined, but there was no evidence
that the degradative enzyme was sensitive to UVA irradiation,
and cGMP or the alternative substrate cAMP was consumed
at the same rate in UVA-irradiated and -unirradiated skin.
Therefore, the target enzyme in the skin for CO derived from
UVA-induced HO-1 appears to be GC.
It is of interest that several earlier studies using inhibitors of
NO synthase have identified a contribution to UVB erythema
of NO produced in UVB-irradiated keratinocytes, or human
and guinea-pig skin, that was associated with increased GC
activity (Deliconstantinos et al., 1997). Inhibition of NO
synthase with N-monomethyl-L-arginine has also been shown
to reduce erythema and to be immunoprotective against UVB
in human subjects (Goldsmith et al., 1996; Halliday et al.,
2004). In contrast, NO or a chemical NO donor molecule
was found to protect mouse and human keratinocytes from
UVB-induced apoptosis, via a GC-dependent mechanism
(Weller et al., 2003). It therefore seems that the cutaneous GC
can be activated by both photoprotective CO and photo-
damaging NO. Future studies will aim to determine the level
of activation of GC by these opposing mediators, to identify
the specificity of PDE isoforms in the responses, to examine
UV waveband specificities, and to investigate possible
compartmentalization of this enzymatic pathway within the
cutaneous strata or cell populations.
MATERIALS AND METHODS
Mice
Female inbred albino Skh:hr-I hairless mice, 6–8 weeks old, were
obtained from the Veterinary Science breeding colony. They were
maintained under conventional animal house conditions in wire-
topped plastic cages on compressed paper bedding (Fibrecycle Pty
Ltd, Mudgeeraba, Queensland) at an ambient temperature of 251C,
and under gold lighting (GEC F40GO) that does not emit any UV
radiation, on a 12-hour on/off cycle. They were fed stock laboratory
mouse pellets (Norco Stockfeeds, Lismore, New South Wales,
Australia) and tap water ad libitum. All procedures were approved
by the University of Sydney Animal Ethics Committee and complied
with the State Animal Research Act 1985.
UV radiation
The UVA source and its spectral properties have been described
previously (Allanson and Reeve, 2004), and consist of a planar bank
of seven 120-cm fluorescent UVA tubes (Hitachi 40 W F40T10BL,
Tokyo, Japan) held in a reflective batten 19 cm above the irradiation
table. The radiation was filtered through a selected sheet of 6 mm
window glass that blocked contaminating wavelengths below
320 nm. This source provided 2.7 103 W/cm2 UVA and
2.3 108 W/cm2 UVB. The UVB radiation source comprised a
single unfiltered UVB tube (Philips TL-40W/12 RS, Eindhoven, The
Netherlands), and provided 1.80 104 W/cm2 UVA and
2.65 104 W/cm2 UVB. The SSUVR source consisted of one
UVB tube flanked by two banks of three UVA tubes, and the
radiation was filtered through a sheet of 0.125 mm cellulose acetate
filter (Eastman Chemical Products, Kingsport, TN) to block contam-
inating wavelengths below 290 nm. This source provided
3.24 103 W/cm2 UVA and 1.78 104 W/cm2 UVB. Irradiance
was measured with an International Light Inc. (Newburyport, MA)
IL1500 radiometer, with UVA and UVB detectors (SE 015/UVA and
SEE 240/UVB) calibrated to the spectral irradiance of the source. The
sources were allowed to stabilize for 15 minutes after switching on,
and the temperature in the irradiation area below the lamps was
stabilized by an electric fan. Groups of up to five mice were exposed
unrestrained in their boxes with the wire tops removed to single
doses of UVA radiation ranging between 1.61 and 1,161 kJ/m2
(exposure times of 1 minute to 12 hours), representing approximately
the UVA content of 0.07–50 MEdD of SSUVR in the hairless
mouse. To assess the photoimmunoprotective effect of UVA, UVA
exposures were followed immediately with a single immunosup-
pressive dose of approximately 3MEdD of either UVB (3.57 kJ/m2)
or SSUVR (69.99 kJ/m2 UVA radiation and 3.85 kJ/m2 UVB radia-
tion), or with topical cis-UCA application as described below. The
MEdDs of UVB and SSUVR were previously established as the
lowest exposure dose resulting in a significant minimally increased
mid-dorsal skinfold thickness at 24 hours measured with a spring
micrometer (Interapid, Geneva, Switzerland). Thus, 3MEdD of
UVB or SSUVR resulted in a moderate but nonburning edematous
erythema at 24 hours. A UVA exposure of 387 kJ/m2 was used in
many experiments, and is equivalent to the UVA content of
16.5MEdD in the hairless mouse, a UVA exposure that could
reasonably be received by humans during a day of prolonged
sunbathing through a UVB-absorbing sunscreen.
Induction of CHS
All mice were sensitized with 0.1 ml of 2% (wt/vol) oxazolone in
ethanol applied to the nonirradiated and nontreated ventral skin on
days 8 and 9 following the UVA, UVB, SSUVR, or cis-UCA treatment
(Reeve and Tyrrell, 1999). On day 15, the prechallenge ear thickness
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was measured using the spring micrometer, followed by application
of 5ml of 2% oxazolone/ethanol to each surface of both pinnae. The
peak ear swelling for the control treatments was determined by
measuring ear thickness repeatedly during 18–24 hours postchal-
lenge, and the group average ear swelling of all treated mice
(postchallenge ear thicknessprechallenge ear thickness) was
determined at this time point.
Cis-UCA treatment
The lotion (a simple cosmetic oil-in-water emulsion) containing
0.2% (wt/vol) of an equilibrium mixture of 60% trans- and 40% cis-
UCA, here referred to as ‘‘cis-UCA’’, and 5% (vol/vol) dimethyl
sulfoxide (DMSO) was prepared as described previously (Reeve
et al., 1993). The control base lotion was identical in composition,
but without added UCA. Aliquots of 0.2 ml of either lotion were
spread evenly over the mouse dorsum using a 1 ml syringe (no
needle) and allowed to be absorbed for 30 minutes. Three
applications were made within 24 hours, to produce an immuno-
suppressive response similar to a single SSUVR exposure.
Cutaneous cGMP immunoassay
Dorsal skin samples were taken at various time points from 0 to
96 hours post-UVA irradiation, or 3 hours after the last topical lotion
application, and were immediately frozen in liquid nitrogen, cut in
10-mm- thick slices using a cryostat at 201C to release cell contents,
weighed frozen, and mixed with the enzymatic reaction buffer (0.1 M
Tris-HCl, pH 8.3, 10 mM MgCl2, and 0.1 M KCl) at a ratio of 1 g wet
weight:5 ml. The tissue suspension was vortexed briefly before
centrifuging at 1,200 g at 41C for 15 minutes. The upper solidified
portion of the skin fats was discarded and the supernatant was
collected and analyzed for cGMP by a commercial ELISA kit (R&D
Systems, Minneapolis, MO).
PDE activity
To determine whether cutaneous PDE was modulated by either UVB
or UVA exposure, PDE enzyme activity with either substrate, cGMP
or cAMP was determined in unirradiated and UVA-irradiated (387 kJ/
m2) skin immediately post-UVA by incubating the skin extracts
prepared as above, with 250 pmol/ml of cGMP or 100 pmol/ml of
cAMP at 371C (Spoto et al., 2003) for 60 minutes. The cGMP or
cAMP that remained following the reaction was determined using a
commercial ELISA cGMP or cAMP kit, respectively (R&D Systems,
Minneapolis, MO), enabling the degraded cGMP and cAMP to be
calculated, and compared with skin extracts inactivated by prior
boiling for 10 minutes.
RT-PCR determination of PDE5 in skin
Skin samples from three hairless mice were frozen, sliced as above,
and RNA extracted by the phenol–chloroform–isoamyl alcohol
method, and analyzed by RT-PCR as previously described for the
detection of HO-1 expression (Allanson and Reeve, 2004). Murine
PDE5 mRNA sequence (accession no. NM_153422) and murine
HO-2 cDNA (as a housekeeping gene; accession no. AF029874) can
be located on the GenBank website (http://www.ncbi.nlm.nih.gov/).
PDE5 primers were designed (forward 50-CCTACCTGGCATTCT
GTGGT-30 and reverse 50-CGCTGTTTCCAGATCAGACA-50) to yield
an 803 bp PCR product. Primers for HO-2 were designed (forward
50-GAAGGAAGGGACCAAGGAAG-30 and reverse 50-GTTTTAGG
CAGAGGTGGAGATG-30) to generate a 767 bp PCR product. The
primers were synthesized by Life Technologies (Melbourne, Aus-
tralia). Electrophoresis employed tris-borate EDTA buffer, pH 8.0, at
80 V for 1 hour at room temperature. Developed gels were
photographed under UV light using a digital camera (Kodak
DC120 Digital).
Topical treatment with CO, ODQ, and sildenafil
Tricarbonyldichlororuthenium (II) dimer ([Ru(CO)3Cl2]2) (Sigma-
Aldrich, Castle Hill, New South Wales, Australia) was dissolved in
DMSO and incorporated into the base lotion to provide a lotion
containing 500mM CO-RM and 10% (vol/vol) DMSO (Allanson and
Reeve, 2005). The GC inhibitor ODQ (Sigma-Aldrich, Castle Hill,
New South Wales, Australia) was also dissolved in DMSO and diluted
in the base lotion to contain 10mM ODQ and 10% DMSO. The PDE5
inhibitor sildenafil (Pfizer Inc., Australia) provided as a 100 mg tablet
was crushed and dissolved in 10 ml DMSO and then diluted in the
base lotion to contain 0.1, 0.01, or 0.001 mg/ml. The control lotions
contained only the equivalent concentration of DMSO.
For CHS measurements, groups of five mice were irradiated on
the dorsum, unrestrained in their boxes with wire cage tops
removed, with 3MEdD of SSUVR (day 1), and subsequently
treated topically on days 1–5 daily with 0.2 ml of sildenafil lotion
(0.01 mg/ml), or with DMSO/base lotion, spread over the dorsum.
For cGMP measurements, groups of three mice were treated
topically on the dorsum with applications of 0.2 ml 500 mM CO-
RM, or 10 mM ODQ or 0.01 mg/ml sildenafil lotions daily for 3 days
and then euthanized 3 hours after the last topical treatment. When
combination treatments of ODQ and CO-RM were given, the ODQ
application preceded the CO-RM, allowing ODQ to be absorbed
first. When UVA irradiation was required, mice were irradiated with
387 kJ/m2 UVA, and euthanized at 48 hours post-UVA; when tested
with ODQ, this was applied immediately post-UVA and repeated on
the next 2 days, and the mice were euthanized at 3 hours after the
last ODQ treatment, that is, at 48 hours post-UVA.
Statistical analysis
The significance of the differences between treatment groups was
evaluated using analysis of variance followed by Tukey’s test (HSD)
with 95% confidence, and Po0.05 regarded as significant.
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